Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice
Authors:
- 2 July 2024
- journal article
- research article
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (5) , 762-765
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma RegistryEuropean Respiratory Journal, 2023
- Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patientsEuropean Respiratory Journal, 2022
- Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma BiologicsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic AsthmaChest, 2020
- Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthmaThorax, 2017
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyAllergy, 2015
- Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult AsthmaInternational Archives of Allergy and Immunology, 2015
- Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma controlRespiratory Medicine, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- After 6 years with Xolair; a 3‐year withdrawal follow‐upAllergy, 2009